By Pierre Bertrand
China's center for drug evaluation will assess an application to market Merck's KGaA's tumor treatment pimicotinib in the country, the company said.
The German life-sciences and electronics company said Tuesday the application was based on results from a first part of global phase 3 study.
The study showed pimicotinib demonstrated a statistically significant improvement in the primary endpoint and statistically significant and clinically meaningful improvements in all secondary endpoints, the company said.
Pimicotinib was granted 'priority review' status by China's Center for Drug Evaluation in May for patients who require systemic therapy.
The treatment is for adult patients with tenosynovial giant cell tumors.
Merck KGaA said it was planning other applications in the U.S. and other markets around the world.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
06-10-25 0134ET
